Fermentas

Former medical product company

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Fermentas" – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message)

|

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "Fermentas" – news · newspapers · books · scholar · JSTOR (July 2020)

|

(Learn how and when to remove this message)

Fermentas

Company type| Public (NYSE: TMO)
Founded| 3 March 1994
Headquarters| Waltham, Massachusetts, USA

Key people

| Marc N. Casper (President & CEO)
Revenue| 1,476,888,454 euro (2022)

Net income

| 554,487,842 euro (2022)
Total assets| 736,264,315 euro (2022)

Number of employees

| 1,520 (2022)
Parent| Thermo Fisher Scientific
Website| www.thermofisher.com
Headquarters in Vilnius

Fermentas was a biotechnology company specializing in the discovery and production of molecular biology products for life science research and diagnostics. Since 2010, Fermentas has been part of Thermo Fisher Scientific.[1]

## Corporate profile

[edit]

In 2003, Fermentas consolidated its international business and set up a controlling enterprise, Fermentas International in Canada. Fermentas International became the shareholder of Fermentas in Vilnius, Lithuania, and its joint ventures in the United States, Canada and Germany (as well as Fermentas China established in 2009).[citation needed]

In 2010, Fermentas International was acquired by Thermo Fisher Scientific. Fermentas, and all of its enterprises, became part of the Analytical Technology segment of the Thermo Fisher.[1]

Fermentas has principal manufacturing operations in Vilnius, Lithuania. More than 99% of production was destined for export markets.[2]

## Products

[edit]

Fermentas is a producer of molecular biology products and is known for its restriction enzymes and DNA ladders and molecular weight markers.[3]

Main products are FastDigest and conventional restriction enzymes, DNA/RNA modifying enzymes, transfection reagents, nucleotides and primers, products of PCR and RT-PCR, molecular cloning, nucleic acid purification, in vitro transcription, molecular labeling and detection, DNA, RNA, protein electrophoresis.[citation needed]

All Fermentas’ products are produced in Class D clean-room facilities, qualified and certified as per EU directives and International Society for Pharmaceutical Engineering (ISPE) guidelines, which are prerequisite for GMP manufacturing. The company is operating under ISO9001, ISO13485 quality and ISO14001 environmental management systems.[4][5]

## References

[edit]

1. ^ a b "Thermo Fisher Scientific to Purchase Fermentas for $260M". Genetic Engineering and Biotechnology News. 27 May 2010.
2. ^ ""Fermentas" gamybą modernizuoja savo lėšomis". DELFI (in Lithuanian). 2006-12-04. Archived from the original on 2023-02-02. Retrieved 2023-02-02.
3. ^ ""Fermentas" pasirengęs šuoliui". Kauno diena (in Lithuanian). 2008-01-15. Archived from the original on 2023-02-02. Retrieved 2023-02-02.
4. ^ "Gamybinė technologinė praktika UAB ,,Thermo Fisher Scientific Baltics". Moksliniaidarbai.lt. 2017-07-16. Archived from the original on 2023-02-02. Retrieved 2023-02-02.
5. ^ tuvuolektis.lt. 2011-09-09 https://web.archive.org/web/20230202224052/http://tuvuolektis.lt/uploads/File/2011-09-09 Pradidinke.pdf. Archived from the original (PDF) on 2023-02-02. Retrieved 2023-02-02. `{{cite web}}`: Missing or empty `|title=` (help)

## External links

[edit]

* Thermo Fisher Scientific Official Site
* Thermo Fisher Scientific Vilnius Site (UAB Fermentas) Official Site